Cargando…

Targeting the Bcl-2 Family in B Cell Lymphoma

Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma subtypes share a set of underlying traits that promote the development and sustain malignant B cells. One of these traits, the ability to evade apoptosis, is essential for lym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adams, Clare M., Clark-Garvey, Sean, Porcu, Pierluigi, Eischen, Christine M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331425/ https://www.ncbi.nlm.nih.gov/pubmed/30671383 http://dx.doi.org/10.3389/fonc.2018.00636

Ejemplares similares

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Editorial: Murine Models of Leukemia and Lymphoma
por: Cutucache, Christine E., et al.
Publicado: (2017)

Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities
por: Rosenberg, Maya, et al.
Publicado: (2023)

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
por: Thomas, Colin, et al.
Publicado: (2023)

Overview of the Use of Murine Models in Leukemia and Lymphoma Research
por: Kohnken, Rebecca, et al.
Publicado: (2017)

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
por: Tessoulin, Benoît, et al.
Publicado: (2019)

Generation of a Murine Model for c-MYC and BCL2 Co-expression B Cell Lymphomas
por: Cai, Zhenming, et al.
Publicado: (2020)

BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role
por: Pileri, Alessandro, et al.
Publicado: (2020)

Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis
por: Zeremski, Vanja, et al.
Publicado: (2023)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
por: Yuan, Delin, et al.
Publicado: (2021)

Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL)
por: Sokol, Kelsey, et al.
Publicado: (2019)

Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?
por: Liu, Hui, et al.
Publicado: (2021)

Crosstalk between Bcl-2 family and Ras family small GTPases: potential cell fate regulation?
por: Kang, Jia, et al.
Publicado: (2013)

miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma
por: McGirt, Laura Y., et al.
Publicado: (2013)

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
por: Zhang, Wei, et al.
Publicado: (2021)

Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma
por: Donati, Giulio, et al.
Publicado: (2021)

2-Deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines
por: Zagorodna, Oksana, et al.
Publicado: (2011)

Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
por: Major, Ajay, et al.
Publicado: (2023)

iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma
por: Liu, Qinhua, et al.
Publicado: (2022)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

The role of BCL-2 family proteins in regulating apoptosis and cancer therapy
por: Qian, Shanna, et al.
Publicado: (2022)

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
por: Dupont, Thibault, et al.
Publicado: (2015)

Cell survival is dicey without Dicer
por: Adams, Clare M, et al.
Publicado: (2014)

Post-translational Modifications of the CARMA1-BCL10-MALT1 Complex in Lymphocytes and Activated B-Cell Like Subtype of Diffuse Large B-Cell Lymphoma
por: Thys, An, et al.
Publicado: (2018)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Treating Cutaneous T-Cell Lymphoma with Highly Irregular Surfaces with Photon Irradiation Using Rice as Tissue Compensator
por: Majithia, Lonika, et al.
Publicado: (2015)

The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma
por: Tyler, Kelly H., et al.
Publicado: (2015)

Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment
por: Anvekar, Rina A., et al.
Publicado: (2011)

Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination
por: Gung, Carol, et al.
Publicado: (2022)

Bcl-B: an “unknown” protein of the Bcl-2 family
por: Pervushin, N. V., et al.
Publicado: (2023)

Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?
por: Shi, Yuanwei, et al.
Publicado: (2022)

Targeting BCL10 by small peptides for the treatment of B cell lymphoma
por: Bao, Wei, et al.
Publicado: (2020)

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
por: Crisci, Stefania, et al.
Publicado: (2019)

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi
por: Ballotta, Laura, et al.
Publicado: (2021)

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
por: Miao, Yi, et al.
Publicado: (2019)

Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
por: Alam, Manzar, et al.
Publicado: (2022)

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
por: Mahmoud, Hanan Mohamed, et al.
Publicado: (2011)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
por: Wobser, M, et al.
Publicado: (2007)

An Optically Pure Apogossypolone Derivative as Potent Pan-Active Inhibitor of Anti-Apoptotic Bcl-2 Family Proteins
por: Wei, Jun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_i70vh1ep835j60rfl1qodf5gb3